{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:22:21Z","timestamp":1793784141763,"version":"4.6.1"},"reference-count":55,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1733,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1742-1241.2010.02587.x","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T09:48:54Z","timestamp":1291369734000},"page":"189-210","source":"Crossref","is-referenced-by-count":106,"title":["Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic"],"prefix":"10.1155","volume":"65","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,3]]},"reference":[{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB1|cit1","unstructured":"United States Food and Drug Administration FDA Approves Latuda to Treat Schizophrenia in Adults http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm231512.htm"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB2|cit2","unstructured":"Sunovion Latuda (lurasidone HCl) Tablets Prescribing Information http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB6|cit6","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB9|cit9","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2010.02.954","article-title":"Detection of drug-placebo difference in schizophrenia clinical trials: site-related factors","volume":"117","author":"Loebel","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB10|cit10","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2010.02.936","article-title":"Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled pearl 2 trial","volume":"117","author":"Cucchiaro","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.schres.2010.02.684","article-title":"Assessment of the maximum tolerated dose (MTD) of lurasidone in patients with schizophrenia","volume":"117","author":"Ereshefsky","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.schres.2010.02.669","article-title":"A three arm dose finding study of lurasidone: efficacy and tolerability data","volume":"117","author":"Harvey","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB13|cit13","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2010.02.425","article-title":"Efficacy of lurasidone in schizophrenia: results of a pooled analysis based on a 5-factor model of schizophrenia","volume":"117","author":"Loebel","year":"2010","journal-title":"Schizophr Res"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB14|cit14","article-title":"Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia","volume":"13","author":"Cucchiaro","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB15|cit15","first-page":"227","article-title":"Efficacy of lurasidone in schizophrenia: summary of results from the clinical development program","volume":"13","author":"Loebel","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB16|cit16","first-page":"342","article-title":"A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder","volume":"35","author":"Cucchiaro","year":"2009","journal-title":"Schizophr Bull"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB17|cit17","first-page":"344","article-title":"Effect of lurasidone on depressive symptoms in patients with schizophrenia","volume":"35","author":"Ogasa","year":"2009","journal-title":"Schizophr Bull"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB18|cit18","article-title":"Performance and interview-based assessments of cognitive change in a randomised, double-blind comparison of lurasidone vs. ziprasidone","volume":"35","author":"Harvey","year":"2009","journal-title":"Schizophr Bull"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB19|cit19","first-page":"373","article-title":"Lurasidone for schizophrenia: symptomatic remission during short-term treatment","volume":"35","author":"Guarino","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB20|cit20","article-title":"Safety of lurasidone in schizophrenia: results of a phase 2, placebo-controlled, study","volume":"33","author":"Ogasa","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB21|cit21","first-page":"572","article-title":"Efficacy of lurasidone in schizophrenia: results of a phase 2, placebo-controlled, study","volume":"33","author":"Phillips","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"S522","DOI":"10.1016\/S0924-977X(05)81090-9","article-title":"Efficacy of lurasidone (SM-13496) in the treatment of schizophrenia: results of two, phase 2, placebo-controlled studies","volume":"15","author":"Ogasa","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2010.02587.x-BIB23|cit23","article-title":"Comparative receptor binding profile of lurasidone and other first and second generation antipsychotics","volume":"13","author":"Ishiyama","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1358\/dof.2008.033.04.1191052","article-title":"Lurasidone hydrochloride. Dopamine D2\/5-HT2A antagonist, treatment of schizophrenia","volume":"33","author":"Cole","year":"2008","journal-title":"Drugs Future"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB25|cit25","unstructured":"Dainippon Sumitomo Pharma Lurasidone Meeting June 12, 2009 Presentation Slides http:\/\/www.ds-pharma.com\/ir\/presentation\/img\/rd.2009.06.pdf"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB26|cit26","unstructured":"Sunovion Lurasidone Demonstrated Efficacy in Treating Patients with Schizophrenia in Pivotal Phase 3 Study http:\/\/www.sunovion.com\/news\/pressReleases-dspa\/20090826.pdf"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB27|cit27","unstructured":"Dainippon Sumitomo Pharma Second Quarter Financial Results for FY2010 (Apr. 1 to Sep. 30, 2010) http:\/\/www.ds-pharma.com\/pdf_view.php?id=55"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB28|cit28","unstructured":"Horisawa T Tokuda K Ishibashi T Ogasa M Silva R Receptor binding profile of lurasidone: a novel psychotropic agent under development for schizophrenia and bipolar disorder"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB29|cit29","unstructured":"Nasrallah HA Cucchiaro J Hsu J Silva R Loebel A Metabolic effects of lurasidone: results from Pearl 1, a double-blind, placebo-controlled 6-week trial in schizophrenia"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB30|cit30","unstructured":"Cucchiaro J Loebel A Silva R Philips D Ogasa M Xu J Efficacy and safety of lurasidone in phase 2\/3 acute schizophrenia trials"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB31|cit31","unstructured":"Horisawa T Tokuda K Ogasa M Ishibashi T Receptor binding profile of lurasidone: a novel psychotropic agent under development for schizophrenia and bipolar disorder"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB32|cit32","unstructured":"Loebel A Cucchiaro J Ogasa M et\u00a0al. Efficacy of lurasidone: summary of results from the clinical development program"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB33|cit33","unstructured":"Preskorn S Chiu YY Sarubbi D Ogasa M Cucchiaro J Loebel A Lurasidone pharmacokinetics: assessment of potential drug-drug interactions"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB34|cit34","unstructured":"Chiu YY Preskorn S Sarubbi D Cucchiaro J Loebel A Effect of food on lurasidone absorption"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/SMJ.0b013e3180f63246","article-title":"Show me the evidence: using number needed to treat","volume":"100","author":"Citrome","year":"2007","journal-title":"South Med J"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuroscience.2007.07.043","article-title":"The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior","volume":"149","author":"Ballaz","year":"2007","journal-title":"Neuroscience"},{"issue":"Suppl. 11","key":"10.1111\/j.1742-1241.2010.02587.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900025086","article-title":"Atypical antipsychotics: matching receptor profile to individual patient\u2019s clinical profile","volume":"9","author":"Shayegan","year":"2004","journal-title":"CNS Spectr"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12325-009-0055-0","article-title":"Using ziprasidone effectively: the food effect and dose-response","volume":"26","author":"Citrome","year":"2009","journal-title":"Adv Ther"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.08m04104","article-title":"The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial","volume":"70","author":"Gandelman","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"122","author":"Citrome","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/j.1742-1241.2010.02501.x","article-title":"Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?","volume":"64","author":"Citrome","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1742-1241.2010.02344.x","article-title":"Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic","volume":"64","author":"Citrome","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/nedt.2006.2.4.427","article-title":"A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder","volume":"2","author":"Citrome","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1742-1241.2009.02142.x","article-title":"Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1111\/j.1742-1241.2010.02587.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","article-title":"Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making","volume":"10","author":"Volavka","year":"2009","journal-title":"Expert Opin Pharmacother"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2010.02587.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2010.02587.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:08:10Z","timestamp":1643332090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2010.02587.x"}},"subtitle":["Lurasidone, review of efficacy and safety"],"short-title":[],"issued":{"date-parts":[[2010,12,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02587.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,3]]}}}